Uso clínico del carvedilol en la hipertensión arterial
No Thumbnail Available
Date
Authors
Advisors
Evaluators
Journal Title
Journal ISSN
Volume Title
Publisher
Universidad Industrial de Santander
Abstract
Description
El carvedilol es un agente betabloqueante ampliamente utilizado en el tratamiento de la insufciencia cardiaca. Numerosos estudios randomizados y controlados han demostrado su efcacia, seguridad y hasta su superioridad sobre otros betabloqueantes tradicionales como el el metoprolol. Sin embargo su uso en la hipertensión arterial curiosamente cuenta con menor nivel y calidad de evidencia científca que en la insufciencia cardiaca. En la presente revisión se consideran aspectos farmacocinéticos, farmacodinámicos y hemodinámicos de los betabloqueantes tradicionales en comparación con el carvedilol. Asimismo, se analiza la evidencia disponible sobre los efectos de este grupo farmacológico respecto del impacto en órganos blanco y su efecto sobre la morbimortalidad cardiovascular.
Palabras clave: Hipertensión. Carvedilol. Betabloqueantes.
Carvedilol is a beta-blocker agent widely used in the treatment of heart failure. Many randomized controlled studies have demonstrated its effcacy, safety and even its superiority over other traditional beta-blockers such as metoprolol. However, its use in hypertension has curiously lower level and quality of scientifc evidence than in heart failure. The present review will consider pharmacokinetic, pharmacodynamic and haemodynamic aspects of traditional beta-blockers compared with carvedilol. It also analyzes the available evidence about the effects of this pharmacological group regard the impact on target organs and its effect on cardiovascular morbidity and mortality. Key words: Hypertension. Carvedilol. Betablockers.
Carvedilol is a beta-blocker agent widely used in the treatment of heart failure. Many randomized controlled studies have demonstrated its effcacy, safety and even its superiority over other traditional beta-blockers such as metoprolol. However, its use in hypertension has curiously lower level and quality of scientifc evidence than in heart failure. The present review will consider pharmacokinetic, pharmacodynamic and haemodynamic aspects of traditional beta-blockers compared with carvedilol. It also analyzes the available evidence about the effects of this pharmacological group regard the impact on target organs and its effect on cardiovascular morbidity and mortality. Key words: Hypertension. Carvedilol. Betablockers.